TrialsgrambetaRCTs are beautiful

ASPRE

2017

Aspirin for Evidence-Based Preeclampsia Prevention trial

In 1,776 women with singleton pregnancies at high risk of preterm pre-eclampsia on first-trimester screening, aspirin 150 mg daily from 11–14 until 36 weeks reduced delivery with pre-eclampsia before 37 weeks compared with placebo.

Result

Efficacy: Delivery with pre-eclampsia before 37 weeks' gestationodds ratio 0.38 (95% CI 0.20-0.74) · P = 0.004

Below 1 favours aspirin 150 mg daily from 11–14 until 36 weeks, above 1 favours placebo.

Event rates
Absolute difference
2.7 points
NNT
38

Absolute difference and NNT are derived from the event rates.

Also reported: No significant difference in neonatal adverse outcomes.

Original publication
Subtopic
Pre-eclampsia prevention
Design
Double-blind, placebo-controlled RCT
Relevance
Important: one of several pillars.
Source
Rolnik DL, Wright D, Poon LC, et al. N Engl J Med. 2017;377(7):613-622.doi 10.1056/NEJMoa1704559

Discussion & critique

The benefit is confined to preterm pre-eclampsia: term disease and hard perinatal outcomes were not significantly reduced, and the trial rests on few events. It established both the effective dose (150 mg, higher than the 75–81 mg used before) and the value of algorithm-based first-trimester screening.